| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 390 |
| 1 | IPILIMUMAB | 304 |
| 2 | CARBOPLATIN | 234 |
| 3 | PACLITAXEL | 156 |
| 4 | PEMETREXED DISODIUM | 84 |
| 5 | PEMETREXED | 75 |
| 6 | DURVALUMAB | 64 |
| 7 | CISPLATIN | 60 |
| 8 | TREMELIMUMAB | 43 |
| 9 | BEVACIZUMAB | 38 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENSITRELVIR | 1 | 0.0556 |
| 1 | MAGNESIUM OXIDE 400MG | 1 | 0.0133 |
| 2 | TREMELIMUMAB | 43 | 0.0097 |
| 3 | IPILIMUMAB | 304 | 0.0069 |
| 4 | NIVOLUMAB | 390 | 0.0040 |
| 5 | NIVOLUMAB AND RELATLIMAB-RMBW | 2 | 0.0039 |
| 6 | NALDEMEDINE | 5 | 0.0030 |
| 7 | DURVALUMAB | 64 | 0.0030 |
| 8 | CLEMASTINE FUMARATE | 4 | 0.0029 |
| 9 | BELINOSTAT | 1 | 0.0028 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 347 | 0.0072 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 392 | 0.0040 |
| 2 | Lymphocyte Activation Gene-3 Blocker [EPC] | 2 | 0.0039 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 64 | 0.0030 |
| 4 | Platinum-based Drug [EPC] | 314 | 0.0011 |
| 5 | Microtubule Inhibitor [EPC] | 163 | 0.0010 |
| 6 | Isocitrate Dehydrogenase 1 Inhibitor [EPC] | 2 | 0.0009 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 5 | 0.0006 |
| 8 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 3 | 0.0005 |
| 9 | Lipid Emulsion [EPC] | 1 | 0.0004 |